BridgeBio Oncology Therapeutics, Inc. BBOT
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 312.88% | 154.88% | 128.05% | 696.00% | 94.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.00% | 99.59% | 98.40% | 150.11% | 26.07% |
| Operating Income | -100.00% | -99.59% | -98.40% | -150.11% | -26.07% |
| Income Before Tax | -98.54% | -90.91% | -97.07% | -158.37% | -30.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -98.54% | -90.91% | -97.07% | -158.37% | -30.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.54% | -90.91% | -97.07% | -158.37% | -30.30% |
| EBIT | -100.00% | -99.59% | -98.40% | -150.11% | -26.07% |
| EBITDA | -100.21% | -99.74% | -98.49% | -150.40% | -26.05% |
| EPS Basic | 99.88% | 99.03% | 99.95% | 99.93% | -223.75% |
| Normalized Basic EPS | 99.88% | 99.03% | 99.95% | 99.93% | -223.75% |
| EPS Diluted | 99.88% | 99.03% | 99.95% | 99.93% | -223.75% |
| Normalized Diluted EPS | 99.88% | 99.03% | 99.95% | 99.93% | -223.75% |
| Average Basic Shares Outstanding | 159,370.12% | 19,578.39% | 436,989.62% | 391,711.71% | -59.74% |
| Average Diluted Shares Outstanding | 159,370.12% | 19,578.39% | 436,989.62% | 391,711.71% | -59.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |